Trial Profile
Crizotinib Outcomes in ALK-Positive Advanced NSCLC Patients with Brain Metastases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Oct 2015 New trial record
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.